axitinib effectively inhibits bcr-abl1t315i distinct binding conformation 
bcr-abl1 fusion gene driver oncogene chronic myeloid leukaemia -% cases adult acute lymphoblastic leukaemia1 introduction abl1 kinase inhibitors example imatinib markedly improved patient survival2 acquired drug resistance remains challenge3- point mutations abl1 kinase domain weaken inhibitor binding6 represent common clinical resistance mechanism bcr-abli kinase domain gatekeeper mutation thr315ile t315i confers resistance approved abl1 inhibitors except ponatinib78 toxicity limitations combine comprehensive drug sensitivity resistance profiling patient cells ex vivo structural analysis establish vegfr tyrosine kinase inhibitor axitinib selective effective inhibitor t315i-mutant bcr-abl1-driven leukaemia axitinib potently inhibited bcr-abl1t315i biochemical cellular levels binding active form abl1 t315i mutation-selective binding mode findings suggest t315i mutation shifts conformational equilibrium kinase favour active dfg-in a-loop conformation optimal binding interactions axitinib treatment t315i chronic myeloid leukaemia patient axitinib resulted rapid reduction t315i-positive cells bone marrow taken together findings demonstrate unexpected opportunity repurpose axitinib anti-angiogenic drug approved renal cancer inhibitor abl1 gatekeeper mutant drug-resistant leukaemia patients study shows wild-type proteins always sample conformations available disease-relevant mutant proteins comprehensive drug testing patient-derived cells can identify unpredictable clinically significant drug-repositioning opportunities 
